Filtered By:
Specialty: Hematology
Condition: Bleeding

This page shows you your search results in order of relevance. This is page number 18.

Order by Relevance | Date

Total 643 results found since Jan 2013.

Screening for clinically relevant drug-drug interactions between direct oral anticoagulants and antineoplastic agents: a pharmacovigilance approach
ConclusionNo signal of DDIs between DOACs and antineoplastic agents was detected, except for DOAC-neratinib. Most DDIs between DOACs and antineoplastic agents may not be clinically relevant. The DDIs between DOACs and neratinib should be further examined in future research.
Source: Journal of Thrombosis and Thrombolysis - August 10, 2023 Category: Hematology Source Type: research

Low bleeding acceptance is associated with increased death risk in patients with atrial fibrillation on oral anticoagulation
AbstractBleeding is the most feared complication of anticoagulation. We sought to investigate whether the bleeding risk acceptance has a prognostic value during long-term follow-up in the era of direct oral anticoagulants (DOACs) among patients with atrial fibrillation (AF). We studied 167 consecutive AF outpatients [aged 68.8 SD 10.6 years; 141 (84.4%) on DOACs]. The bleeding acceptance was assessed based on the Bleeding Ratio defined as the declared maximum number of major bleedings that a patient would be willing to accept to prevent one major stroke. We recorded cerebrovascular ischemic events, major or clinically rele...
Source: Journal of Thrombosis and Thrombolysis - August 19, 2023 Category: Hematology Source Type: research

Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry
CONCLUSION: This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF.PMID:37625457 | DOI:10.1055/s-0043-1772773
Source: Thrombosis and Haemostasis - August 25, 2023 Category: Hematology Authors: Sukrit Treewaree Gregory Y H Lip Rungroj Krittayaphong Source Type: research

Reticulated Platelets Predict Cardiovascular Death and Adverse Events in Coronary Artery Disease: A Systematic Review and Meta-analysis
CONCLUSION: Elevated RPs are significantly associated with increased risk of cardiovascular events and cardiovascular death.PMID:37696301 | DOI:10.1055/s-0043-1773763
Source: Thrombosis and Haemostasis - September 11, 2023 Category: Hematology Authors: Dario Bongiovanni Laura Novelli Francesco Condello Kilian Kirmes Jiaying Han Bastian Wein S ébastien Elvinger Giacomo Viggiani Moritz von Scheidt Karl-Ludwig Laugwitz Philip W J Raake Adnan Kastrati Mauro Chiarito Isabell Bernlochner Source Type: research

Occurrence of thrombosis in congenital thrombocytopenic disorders: a critical annotation of the literature
Patients with a low platelet count are prone to bleeding. The occurrence of a thrombotic event in congenital thrombocytopenic patients is rare and puzzling. At least nine patients with Glanzmann thrombasthenia have been reported to have had a thrombotic event, eight venous and one arterial (intracardiac, in the left ventricle). On the contrary, three patients with Bernard–Soulier syndrome have been shown to have had arterial thrombosis (myocardial infarction) but no venous thrombosis. Finally, seven patients with the familiar macrothrombocytopenia due to alterations of the MYH9 gene have been reported to have had thrombo...
Source: Blood Coagulation and Fibrinolysis - January 1, 2013 Category: Hematology Tags: Original Articles Source Type: research

Tossing a coin or using common sense
Abstract Anticoagulation with warfarin is the leading cause for emergency hospitalizations due to adverse drug events in elderly Americans [1]. In one third of those events warfarin alone or in combination with other dugs was identified as the cause. Antiplatelet agents were the third leading cause (13.3%) and thus in half of the cases antithrombotic therapy was implicated as the cause for emergency hospitalization. Fear of bleeding and old age of the patient are among the most common reasons for not prescribing anticoagulant therapy to patients with atrial fibrillation for whom this kind of stroke prophylaxis is indicated...
Source: Journal of Thrombosis and Haemostasis - January 17, 2013 Category: Hematology Authors: S. Schulman Tags: Commentary Source Type: research

Acute Promyelocytic Leukemia-Associated Thrombosis.
Abstract Patients with acute promyelocytic leukemia (APL) are prone to both bleeding and thrombosis. The bleeding complications are well known. In contrast, APL-associated thrombosis is relatively underappreciated. We aimed to explore the issue of APL-associated thrombosis events. In the past 20 years, 127 cases with APL were found in our hospital database. We collected their coagulation laboratory profiles, including leukemia burdens, white blood cell and platelet counts, prothrombin time, activated partial thromboplastin time, fibrinogen levels, and disseminated intravascular coagulation scores. Data were compar...
Source: Acta Haematologica - January 23, 2013 Category: Hematology Authors: Chang H, Kuo MC, Shih LY, Wu JH, Lin TL, Dunn P, Tang TC, Hung YS, Wang PN Tags: Acta Haematol Source Type: research

Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.This article is protected by copyright. All rights reserved.
Source: Journal of Thrombosis and Haemostasis - April 13, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article ‐ Clinical Haemostasis and Thrombosis Source Type: research

Phase III studies on novel oral anticoagulants for stroke prevention in atrial fibrillation: a look beyond the excellent results. Reply to a rebuttal
We would like to thank Poller et al for his letter and we are happy to reply to their comments. As mentioned by Poller et al many of us participated in the EAA study and are well aware of the results of that study. Time in therapeutic range (TTR) was in fact much higher and bleeding events much lower than those reported in Phase III studies on novel oral anticoagulants (NOAC). However, the aim of our review was to compare the results of the three randomized studies, two of which were double blind double dummy with both the investigators and patients unaware of the type of treatment. © 2013 International Society on Thrombosis and Haemostasis
Source: Journal of Thrombosis and Haemostasis - April 1, 2013 Category: Hematology Authors: V. PENGO, F. MARONGIU, Tags: Letter ‐ Reply to Rebuttal Source Type: research

A specific antidote for dabigatran: functional and structural characterization
Dabigatran etexilate is a direct thrombin inhibitor and used widely as an anticoagulant for the prevention of stroke in patients with atrial fibrillation. However, anticoagulation therapy can be associated with an increased risk of bleeding. Here, we present data on the identification, humanization, and in vitro pharmacology of an antidote for dabigatran (aDabi-Fab). The X-ray crystal structure of dabigatran in complex with the antidote reveals many structural similarities of dabigatran recognition compared with thrombin. By a tighter network of interactions, the antidote achieves an affinity for dabigatran that is ~350 ti...
Source: Blood - May 2, 2013 Category: Hematology Authors: Schiele, F., van Ryn, J., Canada, K., Newsome, C., Sepulveda, E., Park, J., Nar, H., Litzenburger, T. Tags: Plenary Papers, Thrombosis and Hemostasis Source Type: research

Bleeding risks associated with vitamin K antagonists
Abstract: Vitamin K antagonists are widely used for the prevention of stroke due to atrial fibrillation, treatment and secondary prevention of venous thromboembolism, prevention of valvular thromboembolism in patients with prosthetic heart valves, and secondary prevention of acute myocardial infarction. The most common adverse event experienced by patients receiving anticoagulant therapy is major bleeding. The incidence of major bleeding in patients receiving long-term anticoagulation with a vitamin K antagonist in contemporary studies is 1–3% per year. To determine if the benefits of anticoagulant therapy outweigh the r...
Source: Blood Reviews - March 11, 2013 Category: Hematology Authors: Lori-Ann Linkins Source Type: research

Only severe thrombocytopenia results in bleeding and defective thrombus formation in mice
Platelets are essential mediators of hemostasis and thrombosis. Platelet counts (PCs) in humans average 250 platelets/nL, but it is not entirely clear how platelet numbers affect hemostasis and occurrence of thrombotic events. Mice, displaying PCs of ~1000 platelets/nL, are widely used to assess platelet function in (patho-)physiology, but also in this species, the significance of PC for hemostasis and thrombotic disease is not established. We reduced PCs in mice to defined ranges between 0 and 1000 platelets/nL by platelet-depleting antibodies and challenged them in different arterial thrombosis models: the transient midd...
Source: Blood - June 13, 2013 Category: Hematology Authors: Morowski, M., Vogtle, T., Kraft, P., Kleinschnitz, C., Stoll, G., Nieswandt, B. Tags: Thrombocytopenia, Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

Reperfusion of cerebral artery thrombosis by the GPIb-VWF blockade with the Nanobody ALX-0081 reduces brain infarct size in guinea pigs
Thrombolytic therapy is the cornerstone of treatment of acute atherothrombotic ischemic stroke but is associated with brain hemorrhage; antiplatelet therapy has limited efficacy and is still associated with intracranial bleeding. Therefore, new antithrombotic approaches with a better efficacy/safety ratio are required. We have assessed the effect of ALX-0081, a Nanobody against the A1 domain of von Willebrand factor (VWF) that blocks VWF binding to GPIb, of the thrombolytic agent recombinant tissue plasminogen activator (rtPA), and of the GPIIb/IIIa antagonist tirofiban, in a middle cerebral artery (MCA) thrombosis model i...
Source: Blood - June 20, 2013 Category: Hematology Authors: Momi, S., Tantucci, M., Van Roy, M., Ulrichts, H., Ricci, G., Gresele, P. Tags: Platelets and Thrombopoiesis, Thrombosis and Hemostasis Source Type: research

Adherence to anticoagulant treatment with dabigatran in a real‐world setting
ConclusionIn our clinical practice adherence to the twice‐daily dabigatran regimen was generally good, although 12% of the patients had an inadequate adherence. Routine feedback from the pharmacies could inform the physician to improve the anticoagulant management.
Source: Journal of Thrombosis and Haemostasis - July 15, 2013 Category: Hematology Authors: S. Schulman, B. Shortt, M. Robinson, J. W. Eikelboom Tags: Original Article Source Type: research